kneat.com, inc.

KSI

CA4988241010

Software

Market Closed - Toronto S.E. Other stock markets 03:59:58 2024-04-24 pm EDT			5-day change	1st Jan Change
3.75 ^CAD	0.00%		0.00%	+22.95%

Feb. 28	Global Healthcare Leader Selects Kneat	CI
Feb. 23	Kneat.com Maintained at Buy at Stifel GMP After Q4 Results; Price Target Raised to C$4.15	MT

Kneat com : to Exhibit at Swiss Biotech Day 2021

July 22, 2021 at 06:48 am EDT

Swiss Biotech Day 2021

The 2021 Swiss Biotech Day takes place on September 7th.

The Swiss Biotech Day is the leading biotechnology conferences in Switzerland and is a fixed date in the community's calendar. The Swiss Biotech Day is back on stage live this year taking place on September 07^th. You can expect to meet senior experts from the life science industry from across Europe, experience thematically focused panel discussions, observe the Swiss Biotech Success Stories Awards ceremony, and much more. Kneat Solutions is excited to exhibit at this exciting event, come visit us and chat with our validation experts. We look forward to seeing you there!

Attachments

Original document
Permalink

Disclaimer

Kneat.com Inc. published this content on 22 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 July 2021 10:47:08 UTC.

Latest news about kneat.com, inc.

Global Healthcare Leader Selects Kneat	Feb. 28	CI
Kneat.com Maintained at Buy at Stifel GMP After Q4 Results; Price Target Raised to C$4.15	Feb. 23	MT
Transcript : Kneat.com, inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Kneat.com, inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Kneat Brief: Total revenues increased 35% to $9.8 million in Q4 of 2023, compared to $7.3 million for Q4 2022	Feb. 21	MT
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ
Kneat.com Maintained at Buy at Stifel GMP Following Bought-Deal Offering; Price Target Raised to C$4.00	Feb. 15	MT
Toronto Stocks Advance as BOC Holds Rates at 5%, BlackBerry Falls on Convertible Note Offering	Jan. 24	DJ
Kneat Upsized Previously Announced Bought Deal Public Offering to $17.4 Million	Jan. 24	MT
Kneat Brief: Upsized Previously Announced Bought Deal Public Offering to $17.4 Million	Jan. 24	MT
Kneat Announces $15.0 Million Bought Deal Public Offering; Earlier Signed Three-year Master Services Agreement With Global Consumer Products Leader; No Financials Given	Jan. 23	MT
Kneat Brief: Announcing $15.0 Million Bought Deal Public Offering	Jan. 23	MT
Kneat Signs Three-year Master Services Agreement With Global Consumer Products Leader; No Financials Given	Jan. 23	MT
Kneat.Com, Inc. Signs Three-Year Master Services Agreement	Jan. 23	CI
Kneat Brief: Says Signed a three-year Master Services Agreement with a Global Consumer products leader; No Financial Details Given	Jan. 23	MT
Kneat Says Global Consumer Healthcare Leader Selected It to Digitize Its Equipment Commissioning and Qualification Process Across More Than 25 Global Sites	Nov. 27	MT
Kneat Brief: Says Global Consumer Healthcare Leader Selecte Kneat to digitize its equipment Commissioning and Qualification process across more than 25 global site	Nov. 27	MT
Global Consumer Healthcare Leader Selects kneat.com, inc	Nov. 27	CI
Transcript : Kneat.com, inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Kneat.com Third-Quarter Loss Widens Even as Revenue Rises by 46%	Nov. 08	MT
Kneat.com, inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Kneat Brief: Third-quarter 2023 total revenue reaches $8.4 million, an increase of 46% year over year; Net loss for the third quarter of 2023 was ($3.6) million	Nov. 08	MT
Kneat Enters 3-Year Services Agreement with Healthcare Manufacturer and Distributor	23-08-31	MT
Kneat Signs Three-Year Master Services Agreement with Us-Headquartered Manufacturer and Distributor	23-08-30	CI
Transcript : Kneat.com, inc., Q2 2023 Earnings Call, Aug 09, 2023	23-08-09

Chart kneat.com, inc.

Duration

Period

More charts

Company Profile

kneat.com, inc. develops and markets the Kneat Gx software-as-a-service (SaaS) platform. It designs, develops and supplies software for data and document management within regulated environments. The Companyâs focus is to service the facilities, equipment and computer systems (CSV) validation market initially within the global life sciences industry. The Companyâs product is Kneat Gx, a configurable, off-the-shelf application focused on validation lifecycle management and testing primarily within the life sciences industry. Kneat Gx provides a compliant digital solution that enables companies in the life sciences industry to become efficient and compliant with an automated process that has traditionally been manual, inefficient and paper-based. Its various validation processes include electronic logbook management, analytical instrument validation, utility and facility validation, process validation, method validation and equipment validation, cold chain validation, and others.

Sector

Software

Calendar

2024-05-28 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for kneat.com, inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.75 CAD

Average target price

4.358 CAD

Spread / Average Target

+16.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Enterprise Software

	1st Jan change	Capi.
KNEAT.COM, INC.	+22.95%	234M
ORACLE CORPORATION	+9.40%	316B
SAP SE	+25.87%	217B
SERVICENOW, INC.	+5.63%	152B
CONSTELLATION SOFTWARE INC.	+12.53%	57.83B
HUBSPOT, INC.	+12.26%	33.03B
FAIR ISAAC CORPORATION	+2.49%	29.53B
MICROSTRATEGY INCORPORATED	+100.38%	23.61B
WISETECH GLOBAL LIMITED	+21.52%	19.64B
TRIMBLE, INC.	+11.86%	14.58B

Enterprise Software

kneat.com, inc.

Equities

KSI

CA4988241010

Software

Kneat com : to Exhibit at Swiss Biotech Day 2021

EPS Revisions